SCHEMBL4510192

SCHEMBL4510192

CN(C(=O)O)c1ccccc1CBr

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
TP53 P04637 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 2/20 0.37
TSPO P30536 1/20 0.37
POLQ O75417 1/20 0.36
USP2 O75604 1/20 0.36
KMT2A Q03164 3/20 0.36
PTPN1 P18031 1/20 0.35
GSK3B P49841 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11210492 0.86 PTPN1 (0.38) ALDH1A1KDM4ENPC1RAB9ACA12
SCHEMBL8751654 0.85 LMNA (0.43) ALDH1A1KDM4ENPC1RAB9ACA12
SCHEMBL8885290 0.84 HSD11B1 (0.44) ALDH1A1KDM4ENPC1RAB9ATP53
SCHEMBL7705866 0.83 ALDH1A1 (0.39) ALDH1A1KDM4ENPC1RAB9ACA12
SCHEMBL9142099 0.83 PTPN1 (0.37) ALDH1A1KDM4ENPC1RAB9ACA12
SCHEMBL7643329 0.82 GABRA1 (0.44) ALDH1A1KDM4ENPC1RAB9AHPGD
SCHEMBL28272164 0.81 TSPO (0.37) ALDH1A1TP53GAAMAPTTSHR
Hydrochloric Acid SCHEMBL17258978 0.80 KDM4E (0.37) ALDH1A1KDM4ENPC1RAB9ACA12
Ethane SCHEMBL11477742 0.80 ALDH1A1 (0.37) ALDH1A1KDM4ENPC1RAB9ACA12
SCHEMBL9049204 0.80 POLQ (0.39) ALDH1A1KDM4ETP53GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
CN-86108691-A Pyrazole oxime derivatives, process for their preparation and their use NIHON NOHYAKU CO LTD (JP) 1988-01-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 ALDH1A1 51/4885KDM4E 2703/4885NPC1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.